相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Mathilde Bas et al.
JOURNAL OF IMMUNOLOGY (2019)
Immunotherapy for Head and Neck Cancer
Felix Sim et al.
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA (2019)
Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies
Michihiko Aoyama et al.
MABS (2019)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders
Bosco Paes et al.
EUROPEAN JOURNAL OF PEDIATRICS (2019)
Antibodies to watch in 2019
Helene Kaplon et al.
MABS (2019)
Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms
Ryuta Wada et al.
MABS (2019)
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
Tae Hyun Kang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors
Mehabaw G. Derebe et al.
IMMUNOLOGY LETTERS (2018)
Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review
Marcela Helena Gambim Fonseca et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection
Rajeev Gautam et al.
NATURE MEDICINE (2018)
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza et al.
NATURE (2018)
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
Xiang-Qing Yu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
M. Pamela Griffin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antibodies to watch in 2017
Janice M. Reichert
MABS (2017)
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Megan Lo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors
Patricia A. Blundell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities
Gillian Dekkers et al.
FRONTIERS IN IMMUNOLOGY (2017)
Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity
Benjamin Peschke et al.
FRONTIERS IN IMMUNOLOGY (2017)
Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
Yijun Shen et al.
PLOS ONE (2017)
Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality
Susan H. Tam et al.
ANTIBODIES (2017)
Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys
Ivo P. Nnane et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity
S. Giuntini et al.
CLINICAL AND VACCINE IMMUNOLOGY (2016)
Immunoglobulin isotype knowledge and application to Fc engineering
Randall J. Brerski et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
Alysia A. Ahmed et al.
JOURNAL OF STRUCTURAL BIOLOGY (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I
Uwe Wessels et al.
BIOANALYSIS (2016)
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Jonathan T. Sockolosky et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
Isaak Quast et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins
Liming Liu
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
Kevin O. Saunders et al.
JOURNAL OF VIROLOGY (2015)
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding
M. Jack Borrok et al.
MABS (2015)
Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a
E. Arduin et al.
MOLECULAR IMMUNOLOGY (2015)
Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Daniel M. Czajkowsky et al.
SCIENTIFIC REPORTS (2015)
The therapeutic monoclonal antibody market
Dawn M. Ecker et al.
MABS (2015)
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
Gabrielle Romain et al.
BLOOD (2014)
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Stylianos Bournazos et al.
CELL (2014)
IgGA: A Cross-Isotype Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions
William Kelton et al.
CHEMISTRY & BIOLOGY (2014)
Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis
Muthusamy Thiruppathi et al.
JOURNAL OF AUTOIMMUNITY (2014)
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Vaheh Oganesyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Crystal structure of deglycosylated human IgG4-Fc
Anna M. Davies et al.
MOLECULAR IMMUNOLOGY (2014)
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody
Celine Monnet et al.
MABS (2014)
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Sung-Youl Ko et al.
NATURE (2014)
Myeloid cells as effector cells for monoclonal antibody therapy of cancer
Rens Braster et al.
METHODS (2014)
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
Omid Vafa et al.
METHODS (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody- mediated diseases of the newborn
Helga Einarsdottir et al.
TRANSFUSION (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
Sang Taek Jung et al.
ACS CHEMICAL BIOLOGY (2013)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)
Marzieh Niknami et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2013)
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
Futa Mimoto et al.
MABS (2013)
Engineered antibody Fc variant with selectively enhanced FcRIIb binding over both FcRIIaR131 and FcRIIaH131
F. Mimoto et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
M. Jack Borrok et al.
ACS CHEMICAL BIOLOGY (2012)
Marketing approval of mogamulizumab A triumph for glyco-engineering
Alain Beck et al.
MABS (2012)
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Patrick Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice
Ajay Jain et al.
ARTHRITIS RESEARCH & THERAPY (2012)
C1q aggregate binding for the determination of anti-complementary activity of immunoglobulin products
Thanae Georgakopoulos et al.
BIOLOGICALS (2011)
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
Claudia Ferrara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
Nigel M. Stapleton et al.
NATURE COMMUNICATIONS (2011)
Polymeric human Fc-fusion proteins with modified effector functions
David N. A. Mekhaiel et al.
SCIENTIFIC REPORTS (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
Holly M. Horton et al.
BLOOD (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky et al.
NATURE BIOTECHNOLOGY (2010)
Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model
Asahi Ito et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Optimization of Fc-mediated effector functions of monoclonal antibodies
William R. Strohl
CURRENT OPINION IN BIOTECHNOLOGY (2009)
Identity of the elusive IgM Fc receptor (FcμR) in humans
Hiromi Kubagawa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Structure of the Murine Unglycosylated IgG1 Fc Fragment
Matthias J. Feige et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
IgG2m4, an engineered antibody isotype with reduced Fc function
Zhiqiang An et al.
MABS (2009)
Structural characterization of a human Fc fragment engineered for lack of effector functions
Vaheh Oganesyan et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
Holly M. Horton et al.
CANCER RESEARCH (2008)
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
T. Shantha Raju
CURRENT OPINION IN IMMUNOLOGY (2008)
Molecular engineering and design of therapeutic antibodies
Leonard G. Presta
CURRENT OPINION IN IMMUNOLOGY (2008)
Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats
Tomonori Tawara et al.
JOURNAL OF IMMUNOLOGY (2008)
Structural characterization of a mutated, ADCC-enhanced human Fc fragment
Vaheh Oganesyan et al.
MOLECULAR IMMUNOLOGY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell et al.
NATURE (2007)
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types
Yutaka Kanda et al.
GLYCOBIOLOGY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
Christopher T. Rankin et al.
BLOOD (2006)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Modulation of the effector functions of a human IgG1 through engineering of its hinge region
William F. Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2006)
Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy
Y Yamaguchi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms
C Ferrara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer
M Karin et al.
CELL (2006)
Monoclonal antibody successes in the clinic
JM Reichert et al.
NATURE BIOTECHNOLOGY (2005)
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
RJ Ober et al.
JOURNAL OF IMMUNOLOGY (2004)
Human antibody - Fc receptor interactions illuminated by crystal structures
JM Woof et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Structural and functional anatomy of the globular domain of complement protein C1q
W Kishore et al.
IMMUNOLOGY LETTERS (2004)
Structure and activation of the C1 complex of complement: unraveling the puzzle
C Gaboriaud et al.
TRENDS IN IMMUNOLOGY (2004)
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
S Krapp et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
WF Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2002)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Role of oligosaccharide residues of IgG1-Fc in FcγRIIb binding
Y Mimura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions
KR Chintalacharuvu et al.
CLINICAL IMMUNOLOGY (2001)
Expression of GnTIII in a recombinant anti-CD20 CHO production cell line:: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII
J Davies et al.
BIOTECHNOLOGY AND BIOENGINEERING (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4+ T cells in chimpanzees
R Newman et al.
CLINICAL IMMUNOLOGY (2001)
Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation
JE Thommesen et al.
MOLECULAR IMMUNOLOGY (2000)
Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor
AP West et al.
BIOCHEMISTRY (2000)
The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms
Y Mimura et al.
MOLECULAR IMMUNOLOGY (2000)
The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex
P Sondermann et al.
NATURE (2000)
The IgG Fc contains distinct Fc receptor (FcR) binding sites:: The leukocyte receptors FcγRI and FcγRIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A
BD Wines et al.
JOURNAL OF IMMUNOLOGY (2000)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
In vitro characterization of five humanized OKT3 effector function variant antibodies
DL Xu et al.
CELLULAR IMMUNOLOGY (2000)
分享论文
